Colonization and infection with fluoroquinolone-resistant Escherichia coli among cancer patients: Clonal analysis

Infection

Volumn 26, Issue 6, 1998, Pages 379-384

  Oethinger, M ^a   Jellen Ritter, A S ^b   Conrad, S ^b   Marre, R ^b   Kern, W V ^b  

^a Inst F Laboratoriumsmedizin T   (Germany)

^b UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL DNA; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL COLONIZATION; CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; ENTEROBACTER INFECTION; ESCHERICHIA COLI; FECES CULTURE; FEMALE; GASTROINTESTINAL TRACT; GENOTYPE; HUMAN; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; PULSED FIELD GEL ELECTROPHORESIS; RANDOM AMPLIFIED POLYMORPHIC DNA;

EID: 0031773990     PISSN: 03008126     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02770840     Document Type: Article

References (30)

1. Cruciani, M., Cruciani, M., Rampazzo, R., Malena, M., Lazzarini, L., Todeschini, G., Messori, A., Concia, E.: Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: a meta-analysis. Clin. Infect. Dis. 23 (1996) 795-805.
2. Engels, E., Lau, J., Barza, M.: Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis. J. Clin. Oncol. 16 (1998) 1179-1187.
3. Carratalá, J., Fernandez-Sevilla, A., Tubau, F., Dominguez, M. A., Gudiol, F.: Emergence of fluoroquinolone-resistant Escherichia coli in fecal flora of cancer patients receiving norfloxacin prophylaxis. Antimicrob. Agents Chemother. 40 (1996) 503-505.
4. Cometta, A., Calandra, T., Bille, J., Glauser, M. P.: Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia (letter). N. Engl. J. Med. 330 (1994) 1240-1241.
5. Kern, W. V., Andriof, E., Oethinger, M., Kern, P., Hacker, J., Marre, R.: Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center. Antimicrob. Agents Chemother. 38 (1994) 681-687.
6. Oethinger, M., Conrad, S., Kaifel, K., Cometta, A., Bille, J., Klotz, G., Glauser, M. P., Marre, R., Kern, W. V.: Molecular epidemiology of fluoroquinolone-resistant Escherichia coli bloodstream isolates from patients admitted to European cancer centers. Antimicrob. Agents Chemother. 40 (1996) 387-392.
7. Arbeit, R. D., Arthur, M., Dunn, R., Kim, C., Selander, R. K., Goldstein, R.: Resolution of recent evolutionary divergence among Escherichia coli from related lineages: the application of pulsed field electrophoresis to molecular epidemiology. J. Infect. Dis. 161 (1990) 230-235.
8. Gray, L. D.: Escherichia, Salmonella, Shigella, and Yersinia. In: Murray, P., Baron, E. J., Pfaller, M. A., Tenover, F. C., Yolken, R. H. (eds.): Manual of clinical microbiology, 6th ed. American Society for Microbiology, Washington DC 1995, pp. 450-458.
9. National Committee for Clinical Laboratory Standards: Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 2nd ed., approved standard M7-A2. Villanova, PA., NCCLS, 1990.
10. Berg, D. E., Akopyants, N. S., Kersulyte, D.: Fingerprinting microbial genomes using the RAPD or AP-PCR method. Methods. Mol. Cell Biol. 5 (1994) 13-24.
11. Wang, G., Whittam, T. S., Berg, C. M., Berg, D. E.: RAPD (arbitrary primer) PCR is more sensitive than multilocus enzyme electrophoresis for distinguishing related bacterial strains. Nucleic Acids Res. 21 (1993) 5930-5933.
12. Wendt, C., Hollis, R., Pfaller, M., Wenzel, R., Herwaldt, L.: Molecular epidemiology of bacteremia due to Escherichia coli. Abstracts 7th European Congress of Clinical Microbiology and Infectious Diseases, 1995, abstr. 1106.
13. Lindin-Janson, G., Kaijser, B., Lincoln, K., Olling, S., Wedel, H.: The homogeneity of the fecal coliform flora of normal schoolgirls, characterized by serological and biochemical properties. Med. Microbiol. Immunol. 164 (1978) 247-253.
14. Brumfitt, W., Franklin, I., Grady, D., Hamilton-Miller, J. M. T., Iliffe, A.: Changes in the pharmacokinetics of ciprofloxacin and fecal flora during administration of a 7-day course to human volunteers. Antimicrob. Agents Chemother. 26 (1984) 757-761.
15. Pecquet, S., Andrémont, A., Tancrède, C.: Selective antimicrobial modulation of the intestinal tract by norfloxacin in human volunteers and in gnotobiotic mice associated with a human fecal flora. Antimicrob. Agents Chemother. 29 (1986) 1047-1052.
16. Pecquet, S., Andrémont, A., Tancrède, C.: Effect of oral ofloxacin on fecal bacteria in human volunteers. Antimicrob. Agents Chemother. 31 (1987) 124-125.
17. Henning, K. J., Delencastre, H., Eagan, J., Boone, N., Brown, A., Chung, M., Wollner, N., Armstrong, D.: Vancomycin-resistant Enterococcus faecium on a pediatric oncology ward: duration of stool shedding and incidence of clinical shedding. Ped. Infect. Dis. J. 15 (1996) 848-854.
18. Knapp, J. S., Fox, K. K., Trees, D. L., Whittington, W. L.: Fluoroquinolone resistance in Neisseria gonorrhoeae. Emerging Infect. Dis. 3 (1997) 33-39.
19. Karch, H., Russmann, H., Schmidt, H., Schwarzkopf, A., Heesemann, J.: Long-term shedding and clonal turnover of enterohemorrhagic Escherichia coli O157 in diarrheal diseases. J. Clin. Microbiol. 33 (1995) 1602-1605.
20. Caugant, D. A., Levin, B. R., Selander, R. K.: Genetic diversity and temporal variation of Escherichia coli in a human host. Genetics 98 (1981) 467-490.
21. Piddock, L. J. V.: Mechanisms of resistance to fluoroquinolones: state-of-the-art 1992-1994. Drugs 49 (1995)(Suppl 2) 29-35.
22. Heisig, P., Tschorny, R.: Characterization of fluoroquinolone-resistant mutants of Escherichia coli selected in vitro. Antimicrob. Agents Chemother. 38 (1994) 1284-1291.
23. Piddock, L. J. V., Hall, M. C., Walters, R. N.: Phenotypic characterization of quinolone-resistant mutants of Enterobacteriaceae selected from wild-type, gyrA type and multiply-resistant (marA) type strains. J. Antimicrob. Chemother. 28 (1991) 185-198.
24. van Kraaij, M. G. J., Dekker, A. W., Peters, E., Fluit, A., Verdonck, L. F., Rozenberg-Arska, M.: Emergence and complications of ciprofloxacin-resistant Escherichia coli in hematological cancer patients. Program and Abstracts of the 9th International Symposium on Infections in the Immunocompromised Host, 1996, abstr. 034.
25. Kern, W. V., Conrad, S., Oethinger, M., Hay, B., Trautmann, M., Kern, P., Marre, R.: Clinical and molecular epidemiology of fluoroquinolone-resistant Escherichia coli isolated from cancer patients: an update. Program and Abstracts of the 9th International Symposium on Infections in the Immunocompromised Host, Assisi, 1996, abstr. 17.
26. Leigh, D. A., Walsh, B., Hancock, P., Travers, G.: Pharmacokinetics of ofloxacin and the effect on the faecal flora of healthy volunteers. J. Antimicrob. Chemother. 22 (1988) (Suppl C) 115-125.
27. van Saene, J. J. M., van Saene, H. K. F., Leck, C. F.: Inactivation of quinolones by faeces. J. Infect. Dis. 153 (1986) 998-1000.
28. Ball, P.: Is resistant E. coli bacteremia an inevitable outcome for neutropenic patients receiving a fluoroquinolone as prophylaxis? (editorial) Clin. Infect. Dis. 20 (1995) 561-563.
29. Murphy, M., Brown, A. E., Sepkowitz, K. A., Bernard, E. M., Kiehn, T. E., Armstrong, D.: Fluoroquinolone prophylaxis for the prevention of bacterial infection in patients with cancer - is it justified? Clin. Infect. Dis. 25 (1997) 346-347.
30. Kern, W. V.: Epidemiology of fluoroquinolone-resistant Escherichia coli among neutropenic patients. Clin. Infect. Dis. 27 (1998) 235-237.